Chan-Hee Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Chan-Hee Lee has a total of 92 co-authors. Here are the top co-authors by number of shared publications:
- Jang-Won Son
Division of Cardiology, Yeungnam University Medical Center, Yeungnam University College of Medicine , Daegu
9 shared publications - Melvin M. Scheinman
Division of Cardiology, Section of Electrophysiology, University of California San Francisco, San Francisco, CA, USA
9 shared publications - Jong-Seon Park
Division of Cardiology, Yeungnam University Medical Center, Daegu, Republic of Korea
7 shared publications - Ung Kim
Division of Cardiology, Department of Internal Medicine, Yeungnam University Medical Center, Daegu, Korea
7 shared publications - Jong-Ho Nam
Division of Cardiology, Department of Internal Medicine, Yeungnam University Medical Center , Daegu
5 shared publications - Kang-Un Choi
Division of Cardiology, Department of Internal Medicine, Yeungnam University Medical Center, Daegu, Korea
5 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by Korean Association of Internal Medicine in The Korean Journal of Internal Medicine
- Vol. 41 (5) , 884-893
Prognostic significance of artificial intelligence-quantified late gadolinium enhancement on cardiac magnetic resonance in hypertrophic cardiomyopathy
Background/Aims: This study aimed to evaluate the prognostic value of artificial intelligence (AI)-based late gadolinium enhancement (LGE) quantification using cardiovascular magnetic resonance (CMR) in patients with hypertrophic cardiomyopathy (HCM).Methods: We retrospectively analyzed 142 patients with HCM (mean age 58.5 ± 13.7 yr; 72.5% men) who underwent CMR at Yeungnam University Medical Center between 2015 and 2023. LGE was quantified using an AI-based segmentation algorithm with a 6-standard deviation method. Patients were stratified into a high LGE group (≥ 15%) and a low LGE group (< 15%). The primary outcome was a composite of cardiovascular death, including sudden cardiac death (SCD) and SCD-equivalent events.Results: Over a median follow-up of 59 months, the high LGE group experienced a higher incidence of the primary outcome compared with the low LGE group (21.2% vs. 4.6%, p = 0.0067). After adjustment for age and left ventricular ejection fraction, a high AI-quantified LGE burden (≥ 15%) remained independently associated with the primary outcome (adjusted hazard ratio 4.67, 95% confidence interval 1.43–15.30, p = 0.011). Receiver operating characteristic analysis determined an optimal LGE cutoff of 8% for predicting the primary outcome (area under the curve 0.821). Patients with LGE ≥ 8% exhibited markedly increased rates of the primary outcome (18.2% vs. 0%, p < 0.001) and SCD/SCD-equivalent events (13.6% vs. 0%, p = 0.00074).Conclusions: AI-based quantitative assessment of LGE is an independent predictor of adverse cardiovascular outcomes in patients with HCM and may represent a clinically meaningful imaging biomarker for risk stratification.
- 1 September 2026
- Published by Korean Association of Internal Medicine in The Korean Journal of Internal Medicine
- Vol. 41 (5) , 884-893
Open AccessPrognostic significance of artificial intelligence-quantified late gadolinium enhancement on cardiac magnetic resonance in hypertrophic cardiomyopathy
Background/Aims: This study aimed to evaluate the prognostic value of artificial intelligence (AI)-based late gadolinium enhancement (LGE) quantification using cardiovascular magnetic resonance (CMR) in patients with hypertrophic cardiomyopathy (HCM).Methods: We retrospectively analyzed 142 patients with HCM (mean age 58.5 ± 13.7 yr; 72.5% men) who underwent CMR at Yeungnam University Medical Center between 2015 and 2023. LGE was quantified using an AI-based segmentation algorithm with a 6-standard deviation method. Patients were stratified into a high LGE group (≥ 15%) and a low LGE group (< 15%). The primary outcome was a composite of cardiovascular death, including sudden cardiac death (SCD) and SCD-equivalent events.Results: Over a median follow-up of 59 months, the high LGE group experienced a higher incidence of the primary outcome compared with the low LGE group (21.2% vs. 4.6%, p = 0.0067). After adjustment for age and left ventricular ejection fraction, a high AI-quantified LGE burden (≥ 15%) remained independently associated with the primary outcome (adjusted hazard ratio 4.67, 95% confidence interval 1.43–15.30, p = 0.011). Receiver operating characteristic analysis determined an optimal LGE cutoff of 8% for predicting the primary outcome (area under the curve 0.821). Patients with LGE ≥ 8% exhibited markedly increased rates of the primary outcome (18.2% vs. 0%, p < 0.001) and SCD/SCD-equivalent events (13.6% vs. 0%, p = 0.00074).Conclusions: AI-based quantitative assessment of LGE is an independent predictor of adverse cardiovascular outcomes in patients with HCM and may represent a clinically meaningful imaging biomarker for risk stratification.
- Open Access
- 1 March 2026
- Published by Korean Association of Internal Medicine in The Korean Journal of Internal Medicine
- Vol. 41 (2) , 197-209
Pulsed field ablation: focused on atrial fibrillation ablation
Atrial fibrillation (AF) is the most common sustained tachyarrhythmia and its increasing prevalence has resulted in a growing healthcare burden. Catheter ablation is indicated for patients with AF who are either refractory or intolerant to antiarrhythmic drugs or who exhibit decreased left ventricular systolic function. Catheter ablation can be categorized based on the energy source used, including radiofrequency ablation (RFA), cryoablation, laser ablation, and the recently emerging pulsed field ablation (PFA). PFA is anticipated to be promising owing to its tissue specificity, resulting in less collateral damage than thermal energy catheter ablations, such as RFA and cryoablation. In this review, we summarize the biophysical principles and clinical applications of PFA, highlighting its safety and efficacy profile compared to that with conventional thermal ablation.
- 1 March 2026
- Published by Korean Association of Internal Medicine in The Korean Journal of Internal Medicine
- Vol. 41 (2) , 197-209
Open AccessPulsed field ablation: focused on atrial fibrillation ablation
Atrial fibrillation (AF) is the most common sustained tachyarrhythmia and its increasing prevalence has resulted in a growing healthcare burden. Catheter ablation is indicated for patients with AF who are either refractory or intolerant to antiarrhythmic drugs or who exhibit decreased left ventricular systolic function. Catheter ablation can be categorized based on the energy source used, including radiofrequency ablation (RFA), cryoablation, laser ablation, and the recently emerging pulsed field ablation (PFA). PFA is anticipated to be promising owing to its tissue specificity, resulting in less collateral damage than thermal energy catheter ablations, such as RFA and cryoablation. In this review, we summarize the biophysical principles and clinical applications of PFA, highlighting its safety and efficacy profile compared to that with conventional thermal ablation.
- Open Access
- 8 November 2025
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 27 (12)
Sarcopenia in atrial fibrillation: a risk factor for adverse outcomes in a UK Biobank study
Aims: Sarcopenia, characterized by reduced muscle mass and function, has been increasingly implicated in cardiovascular disorders. However, its prognostic relevance in atrial fibrillation (AF) remains unclear. We aimed to evaluate the association between sarcopenia and adverse outcomes in individuals with AF using UK Biobank data. Methods and results: This retrospective cohort study included individuals with AF enrolled between 2006 and 2010 at 22 centres. Sarcopenia was defined per European Working Group on Sarcopenia in Older People 2 (EWGSOP2) criteria as low muscle strength and/or low muscle mass measured by handgrip and bioelectrical impedance analysis. Propensity score weighting adjusted for baseline differences. The primary outcome was a composite of all-cause mortality, major bleeding, thromboembolic events (stroke/systemic embolism), and heart failure admission; each component was also assessed individually. Among 5144 patients with AF (median age, 64.0 years; 24.1% female), 16.7% had sarcopenia. After propensity score weighting, sarcopenia was associated with a higher incidence of the primary composite outcome [43.9 per 1000 person-years (PYRs)], with an adjusted hazard ratio (HR) of 1.30 [95% confidence interval (CI), 1.15–1.46]. This risk was mainly driven by elevated rates of all-cause mortality (26.4 per 1000 PYRs; aHR, 1.44; 95% CI 1.24–1.68) and major bleeding (14.4 per 1000 PYRs; aHR, 1.34; 95% CI 1.10–1.65). Subgroup analyses demonstrated consistent results. Conclusion: Even after PS weighting analysis, some residual confounders may remain; however, sarcopenia was independently associated with adverse clinical outcomes, particularly mortality and bleeding risk. Screening for sarcopenia may enhance risk stratification and management, particularly in patients receiving anticoagulation.
- 8 November 2025
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 27 (12)
Open AccessSarcopenia in atrial fibrillation: a risk factor for adverse outcomes in a UK Biobank study
Aims: Sarcopenia, characterized by reduced muscle mass and function, has been increasingly implicated in cardiovascular disorders. However, its prognostic relevance in atrial fibrillation (AF) remains unclear. We aimed to evaluate the association between sarcopenia and adverse outcomes in individuals with AF using UK Biobank data. Methods and results: This retrospective cohort study included individuals with AF enrolled between 2006 and 2010 at 22 centres. Sarcopenia was defined per European Working Group on Sarcopenia in Older People 2 (EWGSOP2) criteria as low muscle strength and/or low muscle mass measured by handgrip and bioelectrical impedance analysis. Propensity score weighting adjusted for baseline differences. The primary outcome was a composite of all-cause mortality, major bleeding, thromboembolic events (stroke/systemic embolism), and heart failure admission; each component was also assessed individually. Among 5144 patients with AF (median age, 64.0 years; 24.1% female), 16.7% had sarcopenia. After propensity score weighting, sarcopenia was associated with a higher incidence of the primary composite outcome [43.9 per 1000 person-years (PYRs)], with an adjusted hazard ratio (HR) of 1.30 [95% confidence interval (CI), 1.15–1.46]. This risk was mainly driven by elevated rates of all-cause mortality (26.4 per 1000 PYRs; aHR, 1.44; 95% CI 1.24–1.68) and major bleeding (14.4 per 1000 PYRs; aHR, 1.34; 95% CI 1.10–1.65). Subgroup analyses demonstrated consistent results. Conclusion: Even after PS weighting analysis, some residual confounders may remain; however, sarcopenia was independently associated with adverse clinical outcomes, particularly mortality and bleeding risk. Screening for sarcopenia may enhance risk stratification and management, particularly in patients receiving anticoagulation.
- Open Access
- 19 December 2024
- Published by Yeungnam University College of Medicine in Journal of Yeungnam Medical Science
- Vol. 42, 18
Complete or incomplete revascularization in patients with left main culprit lesion acute myocardial infarction with multivessel disease: a retrospective observational study
Background: Complete revascularization has demonstrated better outcomes in patients with acute myocardial infarction (AMI) and multivessel disease. However, in the case of left main (LM) culprit lesion AMI with multivessel disease, there is limited evidence to suggest that complete revascularization is better.Methods: We reviewed 16,831 patients in the Korea Acute Myocardial Infarction Registry who were treated from July 2016 to June 2020, and 399 patients were enrolled with LM culprit lesion AMI treated with percutaneous coronary intervention. We categorized the patients as those treated with complete revascularization (n=295) or incomplete revascularization (n=104). The study endpoint was major adverse cardiac and cerebrovascular events (MACCE), a composite of all-cause death, myocardial infarction, ischemia-driven revascularization, stent thrombosis, and stroke. We performed propensity score matching (PSM) and analyzed the incidence of MACCE at 1 year.Results: After PSM, the two groups were well balanced. There was no significant difference between the two groups in MACCE at 1 year (12.1% vs. 15.2%; hazard ratio, 1.28; 95% confidence interval, 0.60–2.74; p=0.524) after PSM. The components of MACCE and major bleeding were also not significantly different.Conclusion: There was no significant difference in clinical outcomes between the groups treated with complete or incomplete revascularization for LM culprit lesion AMI with multivessel disease.
- 19 December 2024
- Published by Yeungnam University College of Medicine in Journal of Yeungnam Medical Science
- Vol. 42, 18
Open AccessComplete or incomplete revascularization in patients with left main culprit lesion acute myocardial infarction with multivessel disease: a retrospective observational study
Background: Complete revascularization has demonstrated better outcomes in patients with acute myocardial infarction (AMI) and multivessel disease. However, in the case of left main (LM) culprit lesion AMI with multivessel disease, there is limited evidence to suggest that complete revascularization is better.Methods: We reviewed 16,831 patients in the Korea Acute Myocardial Infarction Registry who were treated from July 2016 to June 2020, and 399 patients were enrolled with LM culprit lesion AMI treated with percutaneous coronary intervention. We categorized the patients as those treated with complete revascularization (n=295) or incomplete revascularization (n=104). The study endpoint was major adverse cardiac and cerebrovascular events (MACCE), a composite of all-cause death, myocardial infarction, ischemia-driven revascularization, stent thrombosis, and stroke. We performed propensity score matching (PSM) and analyzed the incidence of MACCE at 1 year.Results: After PSM, the two groups were well balanced. There was no significant difference between the two groups in MACCE at 1 year (12.1% vs. 15.2%; hazard ratio, 1.28; 95% confidence interval, 0.60–2.74; p=0.524) after PSM. The components of MACCE and major bleeding were also not significantly different.Conclusion: There was no significant difference in clinical outcomes between the groups treated with complete or incomplete revascularization for LM culprit lesion AMI with multivessel disease.
- Open Access
- 31 October 2024
- Published by Yeungnam University College of Medicine in Journal of Yeungnam Medical Science
- Vol. 41 (4) , 279-287
Invasive strategies for rhythm control of atrial fibrillation: a narrative review
Atrial fibrillation (AF) is the most common sustained tachyarrhythmia and its increasing prevalence has resulted in a growing healthcare burden. A recent landmark randomized trial, the EAST-AFNET 4 (Early Treatment of Atrial Fibrillation for Stroke Prevention Trial), highlighted the importance of early rhythm control in AF, which was previously underemphasized. Rhythm control therapy includes antiarrhythmic drugs, direct-current cardioversion, and catheter ablation. Currently, catheter ablation is indicated for patients with AF who are either refractory or intolerant to antiarrhythmic drugs or who exhibit decreased left ventricular systolic function. Catheter ablation can be categorized according to the energy source used, including radiofrequency ablation (RFA), cryoablation, laser ablation, and the recently emerging pulsed field ablation (PFA). Catheter ablation techniques can also be divided into the point-by-point ablation method, which ablates the pulmonary vein (PV) antrum one point at a time, and the single-shot technique, which uses a spherical catheter to ablate the PV antrum in a single application. PFA is known to be applicable to both point-by-point and single-shot techniques and is expected to be promising owing to its tissue specificity, resulting in less collateral damage than catheter ablation involving thermal energy, such as RFA and cryoablation. In this review, we aimed to outline catheter ablation for rhythm control in AF by reviewing previous studies.
- 31 October 2024
- Published by Yeungnam University College of Medicine in Journal of Yeungnam Medical Science
- Vol. 41 (4) , 279-287
Open AccessInvasive strategies for rhythm control of atrial fibrillation: a narrative review
Atrial fibrillation (AF) is the most common sustained tachyarrhythmia and its increasing prevalence has resulted in a growing healthcare burden. A recent landmark randomized trial, the EAST-AFNET 4 (Early Treatment of Atrial Fibrillation for Stroke Prevention Trial), highlighted the importance of early rhythm control in AF, which was previously underemphasized. Rhythm control therapy includes antiarrhythmic drugs, direct-current cardioversion, and catheter ablation. Currently, catheter ablation is indicated for patients with AF who are either refractory or intolerant to antiarrhythmic drugs or who exhibit decreased left ventricular systolic function. Catheter ablation can be categorized according to the energy source used, including radiofrequency ablation (RFA), cryoablation, laser ablation, and the recently emerging pulsed field ablation (PFA). Catheter ablation techniques can also be divided into the point-by-point ablation method, which ablates the pulmonary vein (PV) antrum one point at a time, and the single-shot technique, which uses a spherical catheter to ablate the PV antrum in a single application. PFA is known to be applicable to both point-by-point and single-shot techniques and is expected to be promising owing to its tissue specificity, resulting in less collateral damage than catheter ablation involving thermal energy, such as RFA and cryoablation. In this review, we aimed to outline catheter ablation for rhythm control in AF by reviewing previous studies.
- 4 June 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 149 (23) , 1852-1854
A Wide Complex Tachycardia
- 4 June 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 149 (23) , 1852-1854
A Wide Complex Tachycardia
- 19 March 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 149 (12) , 963-966
Wide Complex Tachycardia: Mind Your Medicine!
- 19 March 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 149 (12) , 963-966
Wide Complex Tachycardia: Mind Your Medicine!
- Open Access
- 4 March 2024
- Published by Wiley in Clinical Cardiology
- Vol. 47 (3) , e24248
Cardiovascular outcomes between dapagliflozin versus empagliflozin in patients with diabetes mellitus
Background: Sodium‐glucose co‐transporter 2 (SGLT2) inhibitors have been demonstrated to decrease cardiovascular adverse events. However, there is little real‐world clinical evidence regarding a direct comparison between dapagliflozin and empagliflozin in patients with diabetes mellitus (DM).Hypothesis: A difference in the cardiovascular efficancy of dapagliflozin versus empagliflozin in DM patients was anticipated, aiming to guide the optimal choice of SGLT2 inhibitors based on cardiovascular outcomes.Methods: From 2014 to 2020, a total of 1549 patients with DM who were prescribed SGLT2 inhibitors such as dapagliflozin or empagliflozin were retrospectively enrolled. We categorized the study population into two groups: dapagliflozin (n = 981) and empagliflozin group (n = 568). The primary endpoint was major adverse cardiovascular events (MACE), defined as a composite of all‐cause death, myocardial infarction (MI), stroke, or hospitalization for heart failure (HF) over a 3‐year period.Results: Propensity‐score matching was performed (537 patients in each group). The mean age and hemoglobin A1c were 58.2 ± 13.0 years and 8.4 ± 1.7%, respectively. There was no significant difference between the dapagliflozin and empagliflozin groups in the risk of MACE (3.7% vs. 4.8%, hazard ratio [HR], 1.31; 95% confidence interval [CI], 0.73–2.35; p = 0.349). Furthermore, there were no differences between the two groups in secondary endpoints including all‐cause death, MI, stroke, and hospitalization for HF. Prior MI and history of HF were independent predictors of MACE.Conclusions: Dapagliflozin and empagliflozin showed no significant difference of real‐world clinical cardiovascular outcomes in patients with DM over a 3‐year period. Further large randomized clinical trials will be warranted for better evaluation.
- 4 March 2024
- Published by Wiley in Clinical Cardiology
- Vol. 47 (3) , e24248
Open AccessCardiovascular outcomes between dapagliflozin versus empagliflozin in patients with diabetes mellitus
Background: Sodium‐glucose co‐transporter 2 (SGLT2) inhibitors have been demonstrated to decrease cardiovascular adverse events. However, there is little real‐world clinical evidence regarding a direct comparison between dapagliflozin and empagliflozin in patients with diabetes mellitus (DM).Hypothesis: A difference in the cardiovascular efficancy of dapagliflozin versus empagliflozin in DM patients was anticipated, aiming to guide the optimal choice of SGLT2 inhibitors based on cardiovascular outcomes.Methods: From 2014 to 2020, a total of 1549 patients with DM who were prescribed SGLT2 inhibitors such as dapagliflozin or empagliflozin were retrospectively enrolled. We categorized the study population into two groups: dapagliflozin (n = 981) and empagliflozin group (n = 568). The primary endpoint was major adverse cardiovascular events (MACE), defined as a composite of all‐cause death, myocardial infarction (MI), stroke, or hospitalization for heart failure (HF) over a 3‐year period.Results: Propensity‐score matching was performed (537 patients in each group). The mean age and hemoglobin A1c were 58.2 ± 13.0 years and 8.4 ± 1.7%, respectively. There was no significant difference between the dapagliflozin and empagliflozin groups in the risk of MACE (3.7% vs. 4.8%, hazard ratio [HR], 1.31; 95% confidence interval [CI], 0.73–2.35; p = 0.349). Furthermore, there were no differences between the two groups in secondary endpoints including all‐cause death, MI, stroke, and hospitalization for HF. Prior MI and history of HF were independent predictors of MACE.Conclusions: Dapagliflozin and empagliflozin showed no significant difference of real‐world clinical cardiovascular outcomes in patients with DM over a 3‐year period. Further large randomized clinical trials will be warranted for better evaluation.
- Open Access
- 1 January 2024
- Published by XMLink in Cardiovascular Imaging Asia
- Vol. 8 (1) , 11-14
Exercise-Induced Vasospastic Angina With Prominent Regional Wall Motion Abnormality
Son BJ, et al. Cardiovasc Imaging Asia. 2024 Jan;8(1):11-14. https://doi.org/10.22468/cvia.2023.00094
- 1 January 2024
- Published by XMLink in Cardiovascular Imaging Asia
- Vol. 8 (1) , 11-14
Open AccessExercise-Induced Vasospastic Angina With Prominent Regional Wall Motion Abnormality
Son BJ, et al. Cardiovasc Imaging Asia. 2024 Jan;8(1):11-14. https://doi.org/10.22468/cvia.2023.00094
- 5 December 2023
- Published by Wolters Kluwer Health in Circulation
- Vol. 148 (23) , 1907-1910
A Story With an Interesting Twist
- 5 December 2023
- Published by Wolters Kluwer Health in Circulation
- Vol. 148 (23) , 1907-1910
A Story With an Interesting Twist